Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver cancer
Pharma
Another AstraZeneca Emerald glimmers in liver cancer
Another green light appears increasingly within reach for AZ’s Emerald program, as Imfinzi and Imjudo showed a PFS benefit in locoregional liver cancer.
Angus Liu
Apr 2, 2026 10:12am
Merck, Eisai call it quits on Keytruda-Lenvima in liver cancer type
Oct 29, 2025 11:32am
BMS follows Roche, AstraZeneca into first-line liver cancer
Apr 11, 2025 1:53pm
FDA rejects Hengrui, Elevar's PD-1 cancer drug combo—again
Mar 21, 2025 3:25pm
Merck's Keytruda-Lenvima combo triumphs in liver cancer subtype
Sep 14, 2024 10:30am
UPDATED: Elevar, Hengrui eye accelerated refile for PD-1 combo
Jul 12, 2024 12:08am
